NCT06643143View on ClinicalTrials.gov

A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
DRUG

IkT-001Pro

IkT-001Pro

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

Inhibikase Therapeutics

INDUSTRY

NCT06643143 - A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) | Biotech Hunter | Biotech Hunter